In vitro inhibition of α-Synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole

Bioorg Med Chem Lett. 2024 Jun 1:105:129752. doi: 10.1016/j.bmcl.2024.129752. Epub 2024 Apr 15.

Abstract

The misfolding and aggregation of α-Syn play a pivotal role in connecting diverse pathological pathways in Parkinson's disease (PD). Preserving α-Syn proteostasis and functionality by inhibiting its aggregation or disaggregating existing aggregates using suitable inhibitors represents a promising strategy for PD prevention and treatment. In this study, a series of benzothiazole-polyphenol hybrids was designed and synthesized. Three identified compounds exhibited notable inhibitory activities against α-Syn aggregation in vitro, with IC50 values in the low micromolar range. These inhibitors demonstrated sustained inhibitory effects throughout the entire aggregation process, stabilizing α-Syn proteostasis conformation. Moreover, the compounds effectively disintegrated preformed α-Syn oligomers and fibers, potentially by binding to specific domains within the fibers, inducing fibril instability, collapse, and ultimately resulting in smaller-sized aggregates and monomers. These findings offer valuable insights into the therapeutic potential of polyphenol hybrids with 2-conjugated benzothiazole targeting α-Syn aggregation in the treatment of PD.

Keywords: Disaggregation of preformed α-Syn fibers; Mechanism; Polyphenol hybrids with benzothiazole; Synthesis; α-Syn aggregation inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzothiazoles* / chemical synthesis
  • Benzothiazoles* / chemistry
  • Benzothiazoles* / pharmacology
  • Dose-Response Relationship, Drug
  • Humans
  • Molecular Structure
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Polyphenols* / chemical synthesis
  • Polyphenols* / chemistry
  • Polyphenols* / pharmacology
  • Protein Aggregates* / drug effects
  • Structure-Activity Relationship
  • alpha-Synuclein* / antagonists & inhibitors
  • alpha-Synuclein* / metabolism

Substances

  • Benzothiazoles
  • alpha-Synuclein
  • Polyphenols
  • Protein Aggregates
  • benzothiazole